Time for a systematic look at inactivated HIV vaccines

AIDS

Volumn 29, Issue 1, 2015, Pages 125-127

  Sheppard, Haynes W ^a   Dorman, Burton P ^a  

^a Global Solutions for Infectious Diseases ^*  (United States)

Author keywords

AIDS; HIV; Human immunogenicity microtrials; Inactivated; Killed; Vaccine

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOLOGICAL ADJUVANT; INACTIVATED HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INACTIVATED VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; INACTIVATED VACCINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DRUG ADMINISTRATION ROUTE; EQUINE INFECTIOUS ANEMIA VIRUS; FELINE IMMUNODEFICIENCY VIRUS; HOST CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; NONHUMAN; NOTE; PRIORITY JOURNAL; PRODUCT DEVELOPMENT; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINATION; VACCINE PRODUCTION; VIRUS IMMUNITY; VIRUS INACTIVATION; VIRUS ISOLATION; VIRUS STRAIN; HIV INFECTIONS;

AIDS VACCINES; HIV INFECTIONS; HUMANS; VACCINES, INACTIVATED;

EID: 84926634395     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000476     Document Type: Note

References (26)

1. Rios A, Poteet EC, Siwak EB, Anderson DW, Yao QC. HIV inactivation: time for a second look. AIDS 2015; 29:129-131
2. Rios A, Quesada J, Anderson D, Goldstein A, Fossum T, Colby-Germinario S, et al. Complete inactivation of HIV-1 using photo-labeled nonnucleoside reverse transcriptase inhibitors. Virus Res 2011; 155:189-194
3. Issel CJ, Horohov DW, Lea DF, Adams WV Jr, Hagius SD, McManus JM, et al. Efficacy of inactivated whole-virus and subunit vaccines in preventing infection and disease caused by equine infectious anemia virus. J Virol 1992; 66:3398-3408
4. Uhl EW, Martin M, Coleman JK, Yamamoto JK. Advances in FIV vaccine technology. Vet Immunol Immunopathol 2008; 123:65-80
5. Hosie MJ, Beatty JA. Vaccine protection against feline immunodeficiency virus: setting the challenge. Aust Vet J 2007; 85:5-12
6. Uhl EW, Heaton-Jones TG, Pu R, Yamamoto JK. FIV vaccine development and its importance to veterinary and human medicine: a review. Vet Immunol Immunopathol 2002; 90:113-132
7. Cranage MP, Polyanskaya N, McBride B, Cook N, Ashworth LAE, Dennis M, et al. Studies on the specificity of the vaccine effect elicited by inactivated simian immunodeficiency virus. AIDS Res Human Retrovirus 1993; 9:13-22
8. International AIDS Vaccine Initiative, New York. 'Scientific Blueprint for AIDS Vaccine Development'. June 1998. p
9. Sheppard HW. Inactivated-or killed-virus HIV/AIDS vaccines. Curr Drug Targets Infect Disord 2005; 5:131-141
10. Virgin HW, Walker BD. Immunology and the elusive AIDS vaccine. Nature 2010; 464:224-231
11. Mayne P. HIV vaccine produces no adverse effects in trials. Medical Express 2013; http://m.medicalxpress.com/news/2013-09-hiv-vaccine-adverse-effects-trials.html
12. Clements-Mann ML. Lessons for AIDS vaccine development from non-AIDS vaccines. AIDS Res Hum Retroviruses 1998; 14 (Suppl 3):S197-S203
13. Hilleman MR. A simplified vaccinologist's vaccinology and the pursuit of a vaccine against AIDS. Vaccine 1998; 16:778-793
14. Oshinsky DM. Polio: an American story. New York: Oxford University Press; 2005. p. 17-18 and 121-123
15. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220
16. Barouch DH. The quest for an HIV-1 vaccine: moving forward. N Engl J Med 2013; 369:2073-2076
17. Hammer SM, Sobieszczyk ME, Janes H, Karuna ST, Mulligan MJ, Grove D, et al. Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine. N Engl J Med 2013; 369:2083-2092
18. Van Regenmortel MHV. Requirements for empirical immunogenicity trials, rather than structure-based design, for developing an effective HIV vaccine. Arch Virol 2012; 157: 1-20
19. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, et al. Replication-incompetent adenoviral vaccine vector elicits effective antiimmunodeficiency-virus immunity. Nature 2002; 415:331-335
20. Johnston MI, Fauci AS. An HIV vaccine: challenges and prospects. N Engl J Med 2008; 359:888-890
21. Burton DR, Ahmed R, Barouch DH, Butera ST, Crotty S, Godzik A, et al. A blueprint for HIV vaccine discovery. Cell Host Microbe 2012; 12:396-407
22. Norrby E, Penttinen K. Differences in antibodies to the surface components of mumps virus after immunization with formalininactivated and live virus vaccines. J Infect Dis 1978; 138:672-676
23. Blackburn NK, Besselaar TG. A study of the effect of chemical inactivants on the epitopes of Rift Valley fever virus glycoproteins using monoclonal antibodies. J Virol Meth 1991; 33:367-374
24. Harty JT, Plagemann PGW. Formalin inactivation of the lactate dehydrogenase-elevating virus reveals a major neutralizing epitope not recognized during natural infection. J Virol 1988; 62:3210-3216
25. Sattentau QJ. Conservation of HIV-1 gp120 neutralizing epitopes after formalin inactivation. AIDS 1995; 9:1383-1385
26. Poon B, Hsu JF, Gudeman V, Chen ISY, Grovit-Ferbas K. Formaldehyde-treated, heat-inactivated virions with increased human immunodeficiency virus type 1 Env can be used to induce high-titer neutralizing antibody responses. J Virol 2005; 79:10210-10217.